drugset / Trial / NCT01949545

Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment

NCT01949545

Phase 1 Completed 46 enrolled Amgen
Non-randomizedParallel-groupOpen-labelOther

Summary

The purpose of this study is to compare the safety and efficacy of carfilzomib, including measuring the amount of the study drug in the blood at certain times following dosing. This study is being done in people with varying degrees of liver function to see if they respond differently to the study drug.

Timeline

Start
2013-10
Primary completion
2015-08
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Carfilzomib Other / unclassified 56 mg/m2 Intravenous